Love and fear

mushroms2

Nigel Strauss and Paul Liknaitzky contend that, at least initially, all training should take place within clinical trials overseen by experienced international clinicians and be limited to psychiatrists, psychologists and psychotherapists. Liknaitzky has been developing a program to provide on-the-job training initially for around thirty therapists who will work on the Swinburne and Monash trials and who, he says, will later be able to train others. “These trials are an opportunity to train therapists ethically and rigorously through expert supervision, with real patients, using these drugs.”

“This is such a fragile re-entry back into medicine,” says Ross more generally. “We’ve got one shot at this and that’s why it will take the time that it takes — because it is so easily demonised. You need one bad experience that’s highly publicised, and then we are back at square one. You’ll see a very, very public and swift political backlash, like we did in the seventies. And then it’s all off.”

Click here to read the full article by Kate Cole-Adams

Image: Alamy

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Innovative psychedelic research

The re-emergence of psychedelic research places a crucial emphasis on a holistic approach to mental health from pharmacology, neurobiological process, ecological connection, and therapeutic support.  PRISM supports research and clinical development of therapies where current options provide limited relief.

Your support allows us to pursue cutting edge research for next-generation mental health care.

PRISM

We are a DGR-1 non-profit research charity developing medical and legal processes for the application of psychedelic medicines for improved wellbeing.

Newsletter

Contact Us

Send us an email and we'll get back to you soon.

Not readable? Change text. captcha txt

Start typing and press Enter to search